Cytokine Release Syndrome (CRS) Grading
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Grade 1 - Mild1–1
- Grade 2 - Moderate2–2
- Grade 3 - Severe3–3
- Grade 4 - Life-threatening4–4
The Cytokine Release Syndrome (CRS) Grading calculator is designed for bedside assessing severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic.
Clinical Guidelines & Evidence
Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.
Clinical Indication
The Cytokine Release Syndrome (CRS) Grading is indicated for bedside clinical practice to support Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Treatment should be individualized based on patient comorbidities and clinical status.
CRS Grade determined by highest severity parameter: fever requirement + maximum of (hypotension grade, oxygen requirement grade, organ toxicity grade)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| fever_present | string | Yes | Presence of fever (≥38°C) or fever suppressed by anti-pyretic/anti-cytokine therapy |
| hypotension_status | string | Yes | Hypotension status and intervention requirements |
| oxygen_requirement | string | Yes | Oxygen support requirements |
| organ_toxicity_grade | integer | Yes | Highest grade of organ toxicity (using CTCAE criteria, excluding fever and hypotension) |
| patient_age | integer | No | Patient age in years (for risk stratification)(years) |
| comorbidities_present | string | No | Presence of significant comorbidities that may affect CRS management |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Grade 1 - Mild | Mild symptoms |
| 2–2 | Grade 2 - Moderate | Moderate intervention required |
| 3–3 | Grade 3 - Severe | Aggressive intervention required |
| 4–4 | Grade 4 - Life-threatening | Life-threatening symptoms |
| 5–5 | Grade 5 - Death | Death related to CRS |
Evidence-Based References (EBM)
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758.DOI: 10.1016/j.bbmt.2018.12.758
- Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35. doi: 10.1186/s13045-018-0571-y.DOI: 10.1186/s13045-018-0571-y
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62. doi: 10.1038/nrclinonc.2017.148.DOI: 10.1038/nrclinonc.2017.148
- Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122. doi: 10.1097/PPO.0000000000000035.DOI: 10.1097/PPO.0000000000000035